Cutter Capital Management »

Cytokinetics shares owned by Cutter Capital Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Cutter Capital Management from 13F filings

Historical chart of Cutter Capital Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Cutter Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Cutter Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $13M 237k 54.18

More positions owned by Cutter Capital Management

BioMarin Pharmaceutical (BMRN)
Merck & Co (MRK)
Gilead Sciences (GILD)
Amgen (AMGN)
Royalty Pharma Shs Class A (RPRX)
Biogen Idec (BIIB)
Kenvue (KVUE)
Sarepta Therapeutics (SRPT)
Insmed Com Par $.01 (INSM)
Legend Biotech Corp Sponsored Ads (LEGN)
Ultragenyx Pharmaceutical (RARE)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Cytokinetics Com New (CYTK)
BioCryst Pharmaceuticals (BCRX)
Crispr Therapeutics Namen Akt (CRSP)

View all positions for Cutter Capital Management

Top funds holding Cytokinetics

BlackRock
Vanguard Group
T. Rowe Price Investment Management
State Street Corporation
Darwin Global Management
Bank of America Corporation
Armistice Capital
Geode Capital Management
T. Rowe Price Associates
Pentwater Capital Management
Boxer Capital
Vestal Point Capital
Alliancebernstein
Partner Fund Management
Marshall Wace

View all funds holding Cytokinetics